Teri-Pro Study
Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice.
Related articles
MAT-BH-2100670-V1, September 2021